Muromonab
- Generic Name
- Muromonab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 140608-64-6
- Unique Ingredient Identifier
- JGA39ICE2V
- Background
Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).
- Indication
For treatment of organ transplant recipients, prevention of organ rejection
- Associated Conditions
- Acute Renal Allograft Rejection, Steroid resistant Heart transplant rejection, Steroid resistant hepatic transplant rejection
- Associated Therapies
- -
Tiziana Life Sciences Announces Positive Results from
Tiziana Life Sciences announces positive results for nasal anti-CD3 antibody (foralumab) combined with semaglutide, showing improved liver homeostasis and reduced inflammation in diet-induced obesity models.
Related Clinical Trials:
Tiziana Life Sciences announces $4 million grant awarded by NIH to study anti-CD3 in ...
Tiziana Life Sciences receives $4 million NIH grant for intranasal anti-CD3 research in Alzheimer’s disease, aiming to modulate immune activity and slow progression. The grant supports preclinical and clinical studies, with plans to initiate first-in-human trials in the coming months. Foralumab, a fully human anti-CD3 monoclonal antibody, has shown potential in treating neurodegenerative conditions.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath